A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis

Infection and increased systemic inflammation cause organ dysfunction death in patients with decompensated cirrhosis. Preclinical studies provide support for an antiinflammatory role of albumin, but confirmatory large-scale clinical trials are lacking. Whether targeting a serum albumin level 30 g per liter or greater these repeated daily infusions 20% human solution, as compared standard care, would reduce the incidences infection, kidney dysfunction, is unknown.